As we take stock of masks, gloves, and ventilators, we must ALL be ready to dig deep into our reserves of patience, communication, and compassion. #hapc #graphicmedicine Palliative Care in the Time of COVID inkvessel.com/2020/03/18/pal…

Getting lots on interest in collaborations, so changed my twitter handle for ease of finding. Now Krish Patel. Pls retweet to others who might be interested! Shernan Holtan MD Eric Topol #covid19 #Tocilizumab #rwe #lymsm #pulmcc #IDTwitter

Save Lives w 3D Printed Face Shields gofundme.com/f/cls-3d-faces… Atrium Health #LCI Levine Cancer CharlotteLatinSchool #innovation #CoronavirusPandemic

I have drawn a lot of heavy stuff in the past 2 weeks... here is something I needed to draw to buoy my mood. The Fauci faces pain scale. (Grateful for smart folks like Fauci and hope that the voices of experts can be those that drive our nation’s response to this crisis.)

Congrats to Landon - way to carry this through the finish line! Must credit Matt Tucker (@VUMCHemOnc fellow), who first brought this gene to our attn while doing research with DCI Center for Prostate & Urologic Cancers as a busy SAR Duke IM Residency

Can we ask the insurance companies to place a temporary freeze on peer-to-peer requests during this crisis? I did three of them this week! ASCO Mike Thompson, MD, PhD, FASCO Vincent Rajkumar @drdonsdizon Sumanta K. Pal, MD, FASCO David Gandara Heather Wakelee Lecia Sequist, MD, MPH, FASCO Hossein Borghaei, DO IASLC Taofeek K Owonikoko Wally Curran

A #COVID19 battle story. This week #COVID19 became very real. This virus that has been passed all over the globe and has afflicted more than 1 million people has now infected me. Here, in my corner of the world in Durham, NC. I am 1 of ~300 +cases Duke Health and ~2100 in NC. 1/n

Feel very proud of my friend Petros Grivas Fred Hutch Cancer Center @SeattleCCA for being one of the PIs on a soon to be practice changing trials in met bladder cancer: maintenance avelumab improves OS after platinum chemotherapy. Press release: bit.ly/34nML2S Trial design here👇👇

Poignant op-ed by colleague Nathan Gray MD, FACP on the duality of the struggle as a family man and #palliativecare clinician latimes.com/opinion/story/… #hpm #hapc Duke Palliative Care

Very proud of the PFS/OS positive results announced today for the Phase 3 CheckMate -9ER Trial of #nivolumab/#cabozantinib (combination first done by our group) vs #sunitinib in the 1L treatment of Advanced #RenalCellCarcinoma #kidneycancer | BMS Newsrooms news.bms.com/press-release/…

Today FDA granted accelerated approval to a new dosing regimen of 400 mg every six weeks for pembrolizumab (KEYTRUDA®, Merck) across all currently approved adult indications, in addition to the current 200 mg every three weeks dosing regimen go.usa.gov/xvmYW

Dr. Laura Musselwhite is no stranger to epidemics. With a background in AIDS, Zika and SARS research, she raised her hand to help put together LCI's response plan to COVID-19. Thank you Dr. Musselwhite for your grace and guidance during this time! #MyLCI Atrium Health

Check out our oral presentation today on a novel potential molecular predictor of immune checkpoint response across cancers: LRP1b! DCI Center for Prostate & Urologic Cancers great job Landon C. Brown meetinglibrary.asco.org/record/186713/… and discussion meetinglibrary.asco.org/record/188197/… #ASCO2020 Jason Zhu

Could not have said it better. Has mentored generations of Duke residents and fellows. Generous with ideas, authorship, and most importantly time. Congratulations Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)

Our latest work: Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy advances.sciencemag.org/content/6/27/e…. This is an alternative strategy to bi- and triapecific antibodies. #nkcell #cancerimmunotherapy UNC Lineberger AWangLabUTSW unc.health

Neil Spector, MD, Physician-Scientist, Mentor, Author, Dies at 63 ascopost.com/issues/july-10… Duke Cancer

Surgery Care Division Newsletter Spotlight on CMC UROLOGY 👇 GU Oncology Expansion to Atrium Health University We are so excited to have Justin Matuly join the team!! 👏 MD Anderson Cancer Center

Doubling PFS and ORR and HR 0.6 for OS. Cabozantinib+Nivolumab is now another standard of care for metastatic #kidneycancer. Reassuring that QOL data is improved too. So for Int/Poor risk patients, what combo would you choose? #oncoalert #ESMO2020

ctDNA positivity after cystectomy for muscle invasive bladder cancer identifies a high risk of relapse. These patients have a survival benefit with adjuvant atezolizumab. ctDNA-ve patients have low risk of relapse and don’t benefit from atezo. ctDNA clearance in ~20 #ESMOImmuno20

Why don’t all advanced prostate cancer patients with pathogenic homologous recombination repair (HRR) gene mutations respond to parp inhibitors? Probably because the presence of HRR gene mutations does not always correlate with what is necessary for sensitivity to parp